TY - JOUR
T1 - Weekly updating of guideline recommendations was feasible
T2 - the Australian National COVID-19 clinical evidence Taskforce
AU - Hewitt, Jessie
AU - McDonald, Steve
AU - Poole, Alex
AU - White, Heath
AU - Turner, Simon
AU - Turner, Tari
N1 - Funding Information:
Funding: The taskforce is funded by the Australian Government Department of Health . Foundation funding was provided by the Victorian Government Department of Health and Human Services, The Ian Potter Foundation, Walter Cottman Endowment Fund, managed by Equity Trustees, Lord Mayors' Charitable Foundation. TT is director of the National Clinical Evidence Taskforce, and JH, SM, AP, and HW are members of the taskforce evidence team. All are either fully or partially funded by the taskforce.
Publisher Copyright:
© 2023 The Author(s)
PY - 2023/3
Y1 - 2023/3
N2 - Objectives: To investigate how quickly evidence was incorporated into the Australian living guidelines for COVID-19 during the first 12 months of the pandemic. Study Design and Setting: For each study concerning drug therapies included in the guideline from April 3, 2020 to April 1, 2021, we extracted the publication date of the study, and the guideline version the study was included in. We analyzed two subgroups of studies as follows: those published in high impact factor journals and those with 100 or more participants. Results: In the first year, we published 37 major versions of the guidelines, incorporating 129 studies that investigated 48 drug therapies informing 115 recommendations. The median time from first publication of a study to incorporation in the guideline was 27 days (interquartile range [IQR], 16 to 44), ranging from 9 to 234 days. For the 53 studies in the highest impact factor journals, the median was 20 days (IQR 15 to 30), and for the 71 studies with 100 or more participants the median was 22 days (IQR 15 to 36). Conclusion: Developing and sustaining living guidelines where evidence is rapidly incorporated is a resource- and time-intensive undertaking; however, this study demonstrates that it is feasible, even over a long period.
AB - Objectives: To investigate how quickly evidence was incorporated into the Australian living guidelines for COVID-19 during the first 12 months of the pandemic. Study Design and Setting: For each study concerning drug therapies included in the guideline from April 3, 2020 to April 1, 2021, we extracted the publication date of the study, and the guideline version the study was included in. We analyzed two subgroups of studies as follows: those published in high impact factor journals and those with 100 or more participants. Results: In the first year, we published 37 major versions of the guidelines, incorporating 129 studies that investigated 48 drug therapies informing 115 recommendations. The median time from first publication of a study to incorporation in the guideline was 27 days (interquartile range [IQR], 16 to 44), ranging from 9 to 234 days. For the 53 studies in the highest impact factor journals, the median was 20 days (IQR 15 to 30), and for the 71 studies with 100 or more participants the median was 22 days (IQR 15 to 36). Conclusion: Developing and sustaining living guidelines where evidence is rapidly incorporated is a resource- and time-intensive undertaking; however, this study demonstrates that it is feasible, even over a long period.
KW - COVID-19
KW - Guideline development
KW - Living evidence
KW - Living guidelines
KW - Pandemic
KW - Synthesis
UR - http://www.scopus.com/inward/record.url?scp=85150042116&partnerID=8YFLogxK
U2 - 10.1016/j.jclinepi.2023.02.019
DO - 10.1016/j.jclinepi.2023.02.019
M3 - Article
C2 - 36813003
AN - SCOPUS:85150042116
SN - 0895-4356
VL - 155
SP - 131
EP - 136
JO - Journal of Clinical Epidemiology
JF - Journal of Clinical Epidemiology
ER -